Australia’s next-generation sterile manufacturing platform for GMP-grade IV fluids, Water for Injection (WFI), irrigation solutions, and ready-to-use (RTU) injectables.
Elemental IV is building a sovereign, modular GMP sterile manufacturing facility in South Australia to secure Australia’s supply of critical hospital fluids. Supported through a strategic in-kind equipment partnership with Epic Medical, we are establishing domestic manufacturing capability for products Australia cannot afford to import-depend on again.
Our mission is simple: strengthen supply security, reduce import reliance, and deliver resilient, GMP-certified sterile fluids—Australia first.
Salty Baby Pty Ltd is building Australia’s next-generation sterile manufacturing platform, beginning with GMP-grade intravenous fluids and expanding into high-margin ready-to-use (RTU) compound formulations. Our mission is to establish a sovereign, scalable, and commercially viable supply chain for hospital-critical products—reducing dependency on imports and strengthening national resilience.
In 2025, Salty Baby entered strategic discussions with Epic Medical, a global manufacturer of sterile consumables, to co-anchor Phase 1 infrastructure. Epic has proposed contributing advanced SmartFill and FFS manufacturing systems valued at US$3.1M (A$4.8M), with further capital support to accelerate commissioning. This collaboration delivers immediate manufacturing power while enabling rapid expansion into RTU antibiotics and specialty infusions.
Phase 1 focuses on high-volume SKUs including:
Phase 1.5 expands into RTU antibiotics and sedatives including metronidazole, piperacillin-tazobactam, midazolam, and dexmedetomidine—utilising the same GMP license and modular cleanroom infrastructure.
The leased facility will feature ISO 7/8 modular cleanrooms, SmartFill and FFS bagging lines, and TGA-aligned quality systems, supported by senior GMP consultants with experience across Pfizer, Hospira, and BioCina. The platform is engineered for rapid validation, scalable output, and export readiness from Year 2.
Anchor customers across multiple Australian state health services and Pharmac NZ have already signalled off-cycle procurement interest once licensing is secured—providing rare early demand clarity.
Australia recently experienced its worst IV fluid shortage in over a decade. Hospitals rationed saline. The Federal Government emergency air-freighted 22 million units just to stabilise ICU supply. This crisis exposed a critical vulnerability: near-total national reliance on a single offshore supplier.
Policy has now shifted. Sovereign manufacturing of hospital-critical fluids is no longer optional—it is essential.
Procurement agencies are actively onboarding domestic suppliers capable of delivering:
Elemental IV exists to fill that gap—permanently.
